Economy · News reference
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment
AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.
AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.
AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised